

-2-

AMENDMENT TO THE CLAIMS

1. (Currently Amended): An implantable prosthesis comprising at least one occluder, wherein the at least one occluder comprises a rigid material with pores formed in the rigid material, wherein the rigid material is selected from the group consisting of metals, carbonaceous solids, polymers, and ceramics, wherein a filler comprising a hydrogel, or a structural protein, or a bioactive agent, or mixtures thereof, is located within the pores, wherein said rigid porous material with the filler presents a smoother surface for fluid flow than pores without filler.

2 (Original): The implantable prosthesis of claim 1 wherein the filler fills the pores.

3 (Original): The implantable prosthesis of claim 2 wherein the rigid porous material with the filler presents a smooth surface to flow.

4 (Original): The implantable prosthesis of claim 1 wherein the filler partly fills the pores.

5 (Original): The implantable prosthesis of claim 1 wherein the filler comprises a hydrogel selected from the group consisting of poly(ethylene glycol), poly(hydroxyethyl methacrylate), partially or fully hydrolyzed poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, polyamines, polyacrylamide, hydroxypropylmethacrylate, carboxymethyl cellulose, hydroxyethyl cellulose, methylhydroxypropyl cellulose, polysucrose, hyaluronic acid, alginate, chitosan, dextran, gelatin and mixtures and copolymers thereof.

6 (Original): The implantable prosthesis of claim 1 wherein the filler comprises a structural protein.

7 (Original): The implantable prosthesis of claim 6 wherein the structural protein is an

- 3 -

extracellular matrix protein.

8 (Original): The implantable prosthesis of claim 1 wherein the filler comprises a mixture of hydrogel and structural protein.

9 (Original): The implantable prosthesis of claim 1 wherein the filler comprises a biologically active agent.

10 (Original): The implantable prosthesis of claim 9 wherein the biologically active agent is dispersed within the hydrogel or protein.

11 (Original): The implantable prosthesis of claim 9 wherein the biologically active agent is selected from the group consisting of a growth factor, a cell attraction compound, an anticoagulant and combinations thereof.

12 (Original): The implantable prosthesis of claim 9 wherein the biologically active agent is VEGF.

13 (Original): The implantable prosthesis of claim 9 wherein the bioactive agent is a growth factor.

14 (Original): The implantable prosthesis of claim 9 wherein the bioactive agent is a progenitor attraction compound.

15 (Original): The implantable prosthesis of claim 9 wherein the bioactive agent is an anticoagulant.

16 (Original): The implantable prosthesis of claim 1 wherein the pores extend through the rigid

-4-

material.

17 (Original): The implantable prosthesis of claim 1 wherein the pores have an interconnecting porosity.

18 (Original): The implantable prosthesis of claim 1 wherein a nutrient is also located within the pores.

19 (Original): The implantable prosthesis of claim 1 further comprising viable cells.

20-21 Canceled.

22 (Currently Amended): The implantable prosthesis of claim 1 wherein the prosthesis is a mechanical heart valve prosthesis comprising an orifice ring and ~~a rigid~~ at least one occluder attached to the orifice ring.

23 Canceled.

24-39 Canceled

40 (Currently Amended): An implantable medical device comprising at least one occluder wherein the at least one occluder comprises a rigid material having pores formed in the rigid material and present substantially close to a surface of the rigid material, wherein the rigid material is selected from the group consisting of metals, carbonaceous solids, polymers, and ceramics, and a filler, wherein said filler comprising a hydrogel, ~~or a structural protein, or a~~ bioactive agent, or mixtures thereof, is located within the pores to promote cellular attachment and proliferation.

- 5 -

41 (Previously Presented): The medical device of claim 40 wherein said device is for contacting bodily fluids and/or tissue after implantation.

42 (Previously Presented): The medical device of claim 40 wherein said filler fills the pores.

43 (Previously Presented): The medical device of claim 42 wherein said rigid porous material with the filler presents a smooth surface to flow.

44 (Previously Presented): The medical device of claim 40 wherein said bioactive agent is dispersed within the hydrogel or protein.

45 (Previously Presented): The medical device of claim 40 wherein the bioactive agent is selected from the group consisting of a growth factor, a cell attraction compound, an anticoagulant and combinations thereof.

46 (Previously Presented): The medical device of claim 40 wherein the bioactive agent is VEGF.

47 (Previously Presented): The medical device of claim 40 wherein the bioactive agent is a progenitor attraction compound.

48 (Previously Presented): The medical device of claim 40 wherein the bioactive agent is an anticoagulant.

49 (Currently Amended): An implantable medical device comprising at least one occluder, wherein the at least one occluder comprises a rigid material having pores substantially extending through the rigid material to form a porous network, wherein the rigid material is selected from the group consisting of metals, carbonaceous solids, polymers, and ceramics, and a filler, wherein said filler comprising a hydrogel, or a structural protein, or a bioactive agent, or mixtures

-6-

thereof, is located within the pores, and said porous network does not provide significant blood flow through the porous material.

50 (Previously Presented): The medical device of claim 49 wherein said porous network promotes cellular attachment and proliferation.

51 (Previously Presented): The medical device of claim 49 wherein said filler fills the pores.

52 (Previously Presented): The medical device of claim 51 wherein said rigid porous material with the filler presents a smooth surface to flow.

53 (Previously Presented): The medical device of claim 49 wherein said bioactive agent is dispersed within the hydrogel or protein.

54 (Previously Presented): The medical device of claim 49 wherein the bioactive agent is selected from the group consisting of a growth factor, a cell attraction compound, an anticoagulant and combinations thereof.

55 (Previously Presented): The medical device of claim 49 wherein the bioactive agent is VEGF.

56 (New): The implantable prosthesis of claim 20 wherein the rigid polymer is selected from the group consisting of polysulfones, polyacetals, polyethersulfones, polyarylsulfones, polyetheretherketones, polyamides, polyurethanes, polytetrafluoroethylene, other fluorinated and perfluorinated vinylpolymers, polycarbonate, polyetherimides, tyrosine-derived polyarylate polymers, polylactic acid and polyglycolic acid-based composites and copolymers and mixtures thereof.